Diller G, Orfanos C E
Z Hautkr. 1983 Jun 1;58(11):785-93.
A randomized crossover double-blind study in a selected group of patients with idiopathic urticaria (15 patients; 10 females, 5 males; 20-80 years old) has been performed in order to examine the clinical efficacy of H1 + H2-antagonists in this disease, as compared with the H1-antagonist alone and with placebo. Chlorpheniramine (4 X 4 mg/d) and cimetidine (4 X 400 mg/d) were administered, each of them over 4 weeks, after one week wash-out period. The number of wheals, the time of their persistance as well as the presence of itching were daily registered and then evaluated. The entire group showed no difference between antihistamines and placebo. Nevertheless, 4 patients have registered a definitely better response to the H1-antagonist, 4 other patients responded distinctly better to the combined H1 + H2-treatment and 5 patients showed no preference at all. In a long-term follow up period of 3 months the effect of chlorpheniramine became even better, whereas the response to the combined treatment remained unchanged. It seems that the clinical efficacy of H1 + H2-antagonists is rather moderate in idiopathic urticaria. Nevertheless, in individual cases non-responding to H1-antagonist the combined administration of H1 + H2-antagonists may be more beneficial for the patient.
为了研究H1+H2拮抗剂治疗特发性荨麻疹的临床疗效,并与单独使用H1拮抗剂及安慰剂进行比较,我们对一组特发性荨麻疹患者(15例;女性10例,男性5例;年龄20-80岁)进行了一项随机交叉双盲研究。氯苯那敏(4×4mg/d)和西咪替丁(4×400mg/d)分别给药4周,中间有1周的洗脱期。每天记录风团数量、持续时间以及瘙痒情况,然后进行评估。整个组中抗组胺药与安慰剂之间没有差异。然而,4例患者对H1拮抗剂反应明显更好,另外4例患者对H1+H2联合治疗反应明显更好,5例患者则无明显偏好。在3个月的长期随访期内,氯苯那敏的效果变得更好,而联合治疗的反应保持不变。看来H1+H2拮抗剂治疗特发性荨麻疹的临床疗效相当有限。然而,在个别对H1拮抗剂无反应的病例中,H1+H2拮抗剂联合给药可能对患者更有益。